{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complicated+Urinary+Tract+Infection+%28cUTI%29+Including+Acute+Pyelonephritis",
    "query": {
      "condition": "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T23:23:30.228Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03840148",
      "title": "Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infections",
        "Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Cefepime/VNRX-5133 (taniborbactam)",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Venatorx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 661,
      "start_date": "2019-08-07",
      "completion_date": "2021-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-07-21T23:23:30.228Z",
      "location_count": 4,
      "location_summary": "Buena Park, California • Chula Vista, California • La Mesa, California + 1 more",
      "locations": [
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840148"
    },
    {
      "nct_id": "NCT01595438",
      "title": "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftazidime - Avibactam ( CAZ-AVI)",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)",
          "type": "DRUG"
        },
        {
          "name": "or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 598,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-07-21T23:23:30.228Z",
      "location_count": 3,
      "location_summary": "Sylmar, California • Royal Oak, Michigan • Lima, Ohio",
      "locations": [
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Lima",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01595438"
    },
    {
      "nct_id": "NCT01599806",
      "title": "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftazidime - Avibactam ( CAZ-AVI)",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)",
          "type": "DRUG"
        },
        {
          "name": "or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 641,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-07-21T23:23:30.228Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Indiana",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01599806"
    },
    {
      "nct_id": "NCT02166476",
      "title": "Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection Complicated",
        "Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Meropenem-Vaborbactam",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2014-11-20",
      "completion_date": "2016-04-28",
      "has_results": true,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-07-21T23:23:30.228Z",
      "location_count": 8,
      "location_summary": "Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166476"
    },
    {
      "nct_id": "NCT05204368",
      "title": "Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Combination of Imipenem/Cilastatin and XNW4107",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evopoint Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 780,
      "start_date": "2023-03-30",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-07-21T23:23:30.228Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204368"
    }
  ]
}